Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
April 15, 2024 09:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
April 10, 2024 13:47 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
April 04, 2024 16:00 ET
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Global Cell and Gene Therapy Markets Report 2024-2028 Featuring Main Players - Mallinckrodt, Vericel, Gilead Sciences, Pharmicell, and Bristol-Myers Squibb
April 03, 2024 03:10 ET
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering. The Global Cell and Gene Therapy Market is...
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
March 13, 2024 16:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024 16:05 ET
|
Caribou Biosciences, Inc.
-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for...
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant
March 11, 2024 08:15 ET
|
Napigen, Inc.
The USPTO issued a patent to NAPIGEN for the use of CRISPR technologies to edit organellar genomes. Separately, USDA awarded NAPIGEN an SBIR phase 1 grant.
CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time
March 08, 2024 14:39 ET
|
Pairwise
Durham, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- The panel “The First CRISPR Foods Have Arrived” at this year’s SXSW Conference included leading agricultural scientists, researchers, and innovation...
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024 16:30 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...